Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 201–300 of 1,005
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
“1 0 , 2 0 1 6 Focused Update on Duration of Dual Antiplatelet Therapy S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2 – 1 1 5 1108 syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.”
InfluentialJames, S. K., Roe, M. T., Cannon, C. P., Cornel, J. H., Horrow, J., Husted, S., Katus, H., Morais, J., Steg, P. G., Storey, R. F., et al. (2011) · BMJ · doi:10.1136/bmj.d3527 · Cited by 303
Self-citationAngiolillo, D. J., Bhatt, D. L., Cannon, C. P., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Granger, C. B., Holmes, D. R., Lopes, R. D., Mehran, R., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050438 · Cited by 302
Self-citationFranklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051718 · Cited by 299
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Veitch, A. M., Vanbiervliet, G., Gershlick, A. H., Boustiere, C., Baglin, T. P., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I. M., Hassan, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311110 · Cited by 296
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706443 · Cited by 301
Self-citationEscaned, J., Collet, C., Ryan, N., Luigi De Maria, G., Walsh, S., Sabate, M., Davies, J., Lesiak, M., Moreno, R., Cruz-Gonzalez, I., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx512 · Cited by 294
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
Kubica, J., Adamski, P., Ostrowska, M., Sikora, J., Kubica, J. M., Sroka, W. D., Stankowska, K., Buszko, K., Navarese, E. P., Jilma, B., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv547 · Cited by 287
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 284
Current and future antiplatelet therapies: emphasis on preserving haemostasis
McFadyen, J. D., Schaff, M., & Peter, K. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.206 · Cited by 281
Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome
Bonello, L., Laine, M., Kipson, N., Mancini, J., Helal, O., Fromonot, J., Gariboldi, V., Condo, J., Thuny, F., Frere, C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.067 · Cited by 283
Fauchier, L., Hylek, E., Knight, E., Lane, D., Levi, M., Marin, F., Palareti, G., Collet, J.-P., Rubboli, A., Poli, D., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0690 · Cited by 280
Goto, S., Huang, C.-H., Park, S.-J., Emanuelsson, H., & Kimura, T. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0112 · Cited by 279
Self-citationBasic Principles of Platelet Biology and Clinical Implications
Angiolillo, D. J., Ueno, M., & Goto, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0982 · Cited by 276
Aradi, D., Storey, R. F., Komócsi, A., Trenk, D., Gulba, D., Kiss, R. G., Husted, S., Bonello, L., Sibbing, D., Collet, J.-P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht375 · Cited by 274
Self-citation2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Factors influencing haemorrhagic transformation in ischaemic stroke
Álvarez-Sabín, J., Maisterra, O., Santamarina, E., & Kase, C. S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70055-3 · Cited by 270
Lip, G. Y. H., Collet, J.-P., Haude, M., Byrne, R., Chung, E. H., Fauchier, L., Halvorsen, S., Lau, D., Lopez-Cabanillas, N., Lettino, M., et al. (2019) · EP Europace · doi:10.1093/europace/euy174 · Cited by 274
“of spontaneous bleeding is higher when used in combination with aspirin.(51,52) The PEGASUS-TIMI 54 study assessed a lower dose of ticagrelor (60 mg bid) in addition to the 90 mg bid dose licensed for use in ACS in combination with aspirin (75–150 mg od) in non-AF patients within 1–3 years of MI and at higher risk of…”
Self-citationBauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 266
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Teng, R., Oliver, S., Hayes, M. A., & Butler, K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032250 · Cited by 264
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Jaffer, I. H., & Weitz, J. I. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.021 · Cited by 250
Warner, T. D., Nylander, S., & Whatling, C. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03943.x · Cited by 245
Armstrong, D., Summers, C., Ewart, L., Nylander, S., Sidaway, J. E., & van Giezen, J. J. J. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413511693 · Cited by 245
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology, (. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4103 · Cited by 244
Galli, M., Benenati, S., Capodanno, D., Franchi, F., Rollini, F., D'Amario, D., Porto, I., & Angiolillo, D. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00533-x · Cited by 244
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
Yeung, J., Li, W., & Holinstat, M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014530 · Cited by 242
“…models, by which they reduced venous thrombus formation, has supported the role of platelets in the pathophysiology of venous thrombosis (Herbert et al., 1993; Bernat and Herbert, 1994; Savi et al., 1994, 2000; Imbault et al., 1996; Arroyo et al., 2001; Moore and Deschler, 2007; Wang et al., 2007).”
BackgroundValgimigli, M., Gragnano, F., Branca, M., Franzone, A., Baber, U., Jang, Y., Kimura, T., Hahn, J.-Y., Zhao, Q., Windecker, S., et al. (2021) · BMJ · doi:10.1136/bmj.n1332 · Cited by 242
Non-adherence to cardiovascular medications
Kolandaivelu, K., Leiden, B. B., O'Gara, P. T., & Bhatt, D. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu364 · Cited by 242
Zhao, Q., Zhu, Y., Xu, Z., Cheng, Z., Mei, J., Chen, X., & Wang, X. (2018) · JAMA · doi:10.1001/jama.2018.3197 · Cited by 239
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 241
Self-citationAbraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.010 · Cited by 239
Self-citationAntiplatelet agents for the treatment and prevention of atherothrombosis
Patrono, C., Andreotti, F., Arnesen, H., Badimon, L., Baigent, C., Collet, J.-P., De Caterina, R., Gulba, D., Huber, K., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr373 · Cited by 243
Self-citationAngiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J.-F., Granger, C. B., Mauri, L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034722 · Cited by 238
Self-citationTicagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
Dobesh, P. P., & Oestreich, J. H. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1477 · Cited by 236
De Luca, G., Dirksen, M. T., Spaulding, C., Kelbæk, H., Schalij, M., Thuesen, L., van der Hoeven, B., Vink, M. A., Kaiser, C., Musto, C., et al. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.758 · Cited by 235
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Husted, S., James, S., Becker, R. C., Horrow, J., Katus, H., Storey, R. F., Cannon, C. P., Heras, M., Lopes, R. D., Morais, J., et al. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964395 · Cited by 232
Self-citationClopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Pereira, N. L., Rihal, C. S., So, D. Y. F., Rosenberg, Y., Lennon, R. J., Mathew, V., Goodman, S. G., Weinshilboum, R. M., Wang, L., Baudhuin, L. M., et al. (2019) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.119.007811 · Cited by 227
Evidence Review Committee Members, Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Circulation · doi:10.1161/cir.0000000000000405 · Cited by 227
Hansson, E. C., Jidéus, L., Åberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., Ivert, T., Nozohoor, S., Barbu, M., Svedjeholm, R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv381 · Cited by 226
Writing Committee Members, Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010) · Circulation · doi:10.1161/cir.0b013e3181ee08ed · Cited by 223
Kulik, A., Le May, M. R., Voisine, P., Tardif, J.-C., DeLarochelliere, R., Naidoo, S., Wells, G. A., Mesana, T. G., & Ruel, M. (2010) · Circulation · doi:10.1161/circulationaha.110.978007 · Cited by 221
Lip, G. Y. H., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., Lane, D. A., Levi, M., Marin, F., Palareti, G., et al. (2011) · Europace · doi:10.1093/europace/eur126 · Cited by 223
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., Rockhold, F., Plotnikov, A., Mundl, H., Strony, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30751-1 · Cited by 223
Self-citationVeitch, A., Vanbiervliet, G., Gershlick, A., Boustiere, C., Baglin, T., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I., Hassan, C., et al. (2016) · Endoscopy · doi:10.1055/s-0042-102652 · Cited by 226
Cattaneo, M. (2010) · Circulation · doi:10.1161/circulationaha.109.853069 · Cited by 220
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J.-P., Fitzgerald, D., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 221
“AB BR E V I A T I O N S AND ACRONYM S ACS = acute coronary syndromes CABG = coronary artery bypass graft CAD = coronary artery disease COX = cyclooxygenase DAPT = dual antiplatelet therapy ICH = intracranial hemorrhage MI = myocardial infarction OAC = oral anticoagulation PAD = peripheral artery disease PAR = protease…”
BackgroundInfluentialSelf-citationScirica, B. M., Bonaca, M. P., Braunwald, E., De Ferrari, G. M., Isaza, D., Lewis, B. S., Mehrhof, F., Merlini, P. A., Murphy, S. A., Sabatine, M. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61269-0 · Cited by 217
Self-citationBhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Self-citationAspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 214
Self-citationEvidence-Based Medical Management of Peripheral Artery Disease
Bevan, G. H., & White Solaru, K. T. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312142 · Cited by 211
Kim, C. J., Park, M.-W., Kim, M. C., Choo, E.-H., Hwang, B.-H., Lee, K. Y., Choi, Y. S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01445-8 · Cited by 214
Restenosis, Stent Thrombosis, and Bleeding Complications
Torrado, J., Buckley, L., Durán, A., Trujillo, P., Toldo, S., Valle Raleigh, J., Abbate, A., Biondi-Zoccai, G., & Guzmán, L. A. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.023 · Cited by 212
“The story of 40 years of PCI can be illustrated as Odysseus’s ship navigating through a strait, in which 2 “sea hazards” are situated close enough to each other that they posed an unavoidable threat to passing sailors: avoiding Charybdis (e.g., restenosis) could mean passing too close to Scylla (e.g., thrombosis), as…”
BackgroundInfluentialIntegrating platelet and coagulation activation in fibrin clot formation
Swieringa, F., Spronk, H. M. H., Heemskerk, J. W. M., & van der Meijden, P. E. J. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12107 · Cited by 213
Mehta, S. R., Bainey, K. R., Cantor, W. J., Lordkipanidzé, M., Marquis-Gravel, G., Robinson, S. D., Sibbald, M., So, D. Y., Wong, G. C., Abunassar, J. G., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.012 · Cited by 211
Kim, H.-S., Kang, J., Hwang, D., Han, J.-K., Yang, H.-M., Kang, H.-J., Koo, B.-K., Rhew, J. Y., Chun, K.-J., Lim, Y.-H., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31791-8 · Cited by 209
Park, D.-W., Kwon, O., Jang, J.-S., Yun, S.-C., Park, H., Kang, D.-Y., Ahn, J.-M., Lee, P. H., Lee, S.-W., Park, S.-W., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041766 · Cited by 208
Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31887-2 · Cited by 209
Self-citationLindholm, D., Varenhorst, C., Cannon, C. P., Harrington, R. A., Himmelmann, A., Maya, J., Husted, S., Steg, P. G., Cornel, J. H., Storey, R. F., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu160 · Cited by 208
Self-citationClaessen, B. E., Henriques, J. P. S., Jaffer, F. A., Mehran, R., Piek, J. J., & Dangas, G. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.05.016 · Cited by 207
Storey, R. F., Becker, R. C., Harrington, R. A., Husted, S., James, S. K., Cools, F., Steg, P. G., Khurmi, N. S., Emanuelsson, H., Cooper, A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr231 · Cited by 207
Self-citationPlatelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective
Kakouros, N., Rade, J. J., Kourliouros, A., & Resar, J. R. (2011) · International Journal of Endocrinology · doi:10.1155/2011/742719 · Cited by 205
Eikelboom, J., Berger, P., Holmes, D., Bhatt, D., Becker, R., Angiolill, D., Faxon, D., & Moliterno, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0262 · Cited by 204
Self-citationAntiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period
Hall, R., & Mazer, C. D. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318203f38d · Cited by 203
Motovska, Z., Hlinomaz, O., Miklik, R., Hromadka, M., Varvarovsky, I., Dusek, J., Knot, J., Jarkovsky, J., Kala, P., Rokyta, R., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024823 · Cited by 203
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort
Smith, P. K., Goodnough, L. T., Levy, J. H., Poston, R. S., Short, M. A., Weerakkody, G. J., & LeNarz, L. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.030 · Cited by 203
Recent advances in the diagnosis and treatment of acute myocardial infarction
Reddy, K. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i5.243 · Cited by 200
Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., & Sundstrom, J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht049 · Cited by 198
Self-citationvan Giezen, J. J. J., Sidaway, J., Glaves, P., Kirk, I., & Björkman, J.-A. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411410883 · Cited by 198
Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans
Wittfeldt, A., Emanuelsson, H., Brandrup-Wognsen, G., van Giezen, J. J. J., Jonasson, J., Nylander, S., & Gan, L.-M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.032 · Cited by 198
Self-citationTepe, G., Bantleon, R., Brechtel, K., Schmehl, J., Zeller, T., Claussen, C. D., & Strobl, F. F. (2012) · European Radiology · doi:10.1007/s00330-012-2441-2 · Cited by 196
Cavender, M. A., & Sabatine, M. S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61216-2 · Cited by 198
Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes
Notarangelo, F. M., Maglietta, G., Bevilacqua, P., Cereda, M., Merlini, P. A., Villani, G. Q., Moruzzi, P., Patrizi, G., Malagoli Tagliazucchi, G., Crocamo, A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.029 · Cited by 196
“Because ticagrelor proved to be more effective than clopidogrel in the PLATO trial (17), it is possible that some of the benefit observed in the present study may have been related to the more frequent use of clopidogrel in the”
The role of platelets in the recruitment of leukocytes during vascular disease
Ed Rainger, G., Chimen, M., Harrison, M. J., Yates, C. M., Harrison, P., Watson, S. P., Lordkipanidzé, M., & Nash, G. B. (2015) · Platelets · doi:10.3109/09537104.2015.1064881 · Cited by 194
Cattaneo, M., Chassot, P.-G., Eichinger, S., Heymann, C. V., Hofmann, N., Rickli, H., Spannagl, M., Ziegler, B., Verheugt, F., Huber, K., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-04-0217 · Cited by 196
Teng, R., & Butler, K. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0778-5 · Cited by 196
Association of MicroRNAs and YRNAs With Platelet Function
Kaudewitz, D., Skroblin, P., Bender, L. H., Barwari, T., Willeit, P., Pechlaner, R., Sunderland, N. P., Willeit, K., Morton, A. C., Armstrong, P. C., et al. (2016) · Circulation Research · doi:10.1161/circresaha.114.305663 · Cited by 195
Self-citationAmarenco, P., Albers, G. W., Denison, H., Easton, J. D., Evans, S. R., Held, P., Hill, M. D., Jonasson, J., Kasner, S. E., Ladenvall, P., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30038-8 · Cited by 198
Goodman, S. G., Clare, R., Pieper, K. S., Nicolau, J. C., Storey, R. F., Cantor, W. J., Mahaffey, K. W., Angiolillo, D. J., Husted, S., Cannon, C. P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.032912 · Cited by 194
Self-citationBittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.512 · Cited by 194
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 192
Alexopoulos, D., Galati, A., Xanthopoulou, I., Mavronasiou, E., Kassimis, G., Theodoropoulos, K. C., Makris, G., Damelou, A., Tsigkas, G., Hahalis, G., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.050 · Cited by 193
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
Cattaneo, M. (2011) · Blood · doi:10.1182/blood-2010-08-263111 · Cited by 191
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.032 · Cited by 188
“9% rate of recurrent MI at 12 months.(7) In 2010 alone, about 595 000 inpatient hospital discharges were attributed to AMI.”
BackgroundInfluentialChan, F. K. L., Goh, K.-L., Reddy, N., Fujimoto, K., Ho, K. Y., Hokimoto, S., Jeong, Y.-H., Kitazono, T., Lee, H. S., Mahachai, V., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315131 · Cited by 188
Harold, J. G., Bass, T. A., Bashore, T. M., Brindis, R. G., Brush, J. E., Burke, J. A., Dehmer, G. J., Deychak, Y. A., Jneid, H., Jollis, J. G., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.002 · Cited by 187
De Luca, G., Damen, S. A., Camaro, C., Benit, E., Verdoia, M., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A., Zambahari, R., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00539 · Cited by 187
Sibbing, D., Koch, W., Massberg, S., Byrne, R. A., Mehilli, J., Schulz, S., Mayer, K., Bernlochner, I., Schomig, A., & Kastrati, A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr155 · Cited by 185
Steg, P. G., Mehta, S. R., Jukema, J. W., Lip, G. Y. H., Gibson, C. M., Kovar, F., Kala, P., Garcia-Hernandez, A., Renfurm, R. W., & Granger, C. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr334 · Cited by 186
Self-citationBaber, U., Dangas, G., Angiolillo, D. J., Cohen, D. J., Sharma, S. K., Nicolas, J., Briguori, C., Cha, J. Y., Collier, T., Dudek, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa670 · Cited by 185
Self-citationStorey, R. F., Bliden, K. P., Patil, S. B., Karunakaran, A., Ecob, R., Butler, K., Teng, R., Wei, C., Tantry, U. S., & Gurbel, P. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.062 · Cited by 186
Self-citationGe, Z., Kan, J., Gao, X., Raza, A., Zhang, J.-J., Mohydin, B. S., Gao, F., Shao, Y., Wang, Y., Zeng, H., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00473-2 · Cited by 183
Hematopoiesis and Cardiovascular Disease
Poller, W. C., Nahrendorf, M., & Swirski, F. K. (2020) · Circulation Research · doi:10.1161/circresaha.120.315895 · Cited by 184
Jeong, Y.-H. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0485-4 · Cited by 183
Hochholzer, W., Wiviott, S. D., Antman, E. M., Contant, C. F., Guo, J., Giugliano, R. P., Dalby, A. J., Montalescot, G., & Braunwald, E. (2011) · Circulation · doi:10.1161/circulationaha.110.002683 · Cited by 183
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.